Company profile for Golden Age Health

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Golden Age Health (GAH) is a pharmaceutical company dedicated to commercializing innovative treatments for rare and specialty diseases, with a focus on China, Asia, and the Middle East. Backed by a team of global pharma veterans and strong local expertise, GAH bridges the gap in patient access by bringing proven therapies to underserved regions. The company offers flexible collaboration models and end-to-end commercialization ...
Golden Age Health (GAH) is a pharmaceutical company dedicated to commercializing innovative treatments for rare and specialty diseases, with a focus on China, Asia, and the Middle East. Backed by a team of global pharma veterans and strong local expertise, GAH bridges the gap in patient access by bringing proven therapies to underserved regions. The company offers flexible collaboration models and end-to-end commercialization services, including regulatory support, market access, patient engagement, and real-world evidence generation.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Singapore
Address
Address
400 Orchard Road #05-12 Orchard Towers
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-02-01/tenacia-biopharmaceuticals-and-golden-age-health-partner-to-commercialize-ztalmy-for-cdkl5-deficien

PHARMIWEB
01 Feb 2026

https://www.businesswire.com/news/home/20250714880327/en/Golden-Age-Health-and-Innostellar-Biotherapeutics-Sign-Exclusive-10-Year-Collaboration-to-Accelerate-LX-101-Gene-Therapy-for-Inherited-Retinal-Dystrophies-due-to-RPE-65-gene-mutation-in-Mainland-China

BUSINESSWIRE
13 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty